Reference Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Ref Type
PMID
Authors E.P. Hamilton, S. Goel, R. Arend, C. Chu, D.L. Richardson, J.R. Diamond, V. John, F. Janku, C. Matthews, L. JeBailey, K. Kuida, H. Achour, R. Ruiz-Soto, J. Hays
Title A phase Ib/II study of rebastinib and paclitaxel in advanced or metastatic platinum-resistant ovarian cancer
Journal Annals of Oncology
Vol 31
Issue suppl_4
Date
URL https://www.sciencedirect.com/science/article/pii/S0923753420409743
Abstract Text Background: Rebastinib is a switch control inhibitor of TIE2 kinase. TIE2 is expressed in endothelial cells and in some macrophages with pro-angiogenic, pro-metastatic and immunosuppressive properties associated with chemotherapy resistance. This is a 2-part open-label, phase Ib/II study with orally administered rebastinib in combination with weekly paclitaxel 80 mg/m2. In part 1, we observed antitumor activity across multiple tumor types (5 PRs in 24 pts at 50 mg BID and 3 PRs in 19 pts at 100 mg BID), including 3 PRs in platinum-resistant ovarian cancer (PROC). Part 2 has 5 cohorts: TNBC, inflammatory breast cancer, PROC, endometrial cancer and carcinosarcoma. Here, we present preliminary results from the PROC cohort. Methods: Part 2 is a Simon 2-stage design enrolling 18 pts into the first stage, and if ≥5 responses, an additional 15 pts in the second stage. Pts were treated with rebastinib in combination with paclitaxel 80 mg/m2 intravenous weekly (D1, D8, D15 of repeated 28-day cycles) and evaluated for safety (CTCAE v5.0) and efficacy (RECIST v1.1). Results: As of March 20, 2020, 20 pts were enrolled; the median age was 58 years. All received ≥ 1 prior regimen with paclitaxel/carboplatin; the median number of prior therapies was 5 (2, 7). Ten pts were initially treated with 100 mg BID rebastinib (reduced to 50 mg BID due to muscular weakness [4 pts in this cohort]) and 10 pts with 50 mg BID with a treatment median duration of 16 weeks (0.7, 31.9). In 17 evaluable pts, there were 5 PRs and 9 SDs (at 8 weeks) for an ORR of 29% and CBR of 82%. In addition, 8/13 (62%) pts had a CA-125 response. TEAEs (≥n=5) were mostly ≤ grade 2, including fatigue (n=8), nausea (n=8), diarrhea, dry mouth, peripheral sensory neuropathy, vomiting (n=6 each); abdominal pain, alopecia, constipation, peripheral edema and stomatitis (n=5 each). Serious AEs possibly related to rebastinib included grade 2, reversible muscular weakness (at 100 mg BID with no additional occurrences at rebastinib 50 mg BID), fatigue and constipation (n=1 each). Conclusions: The preliminary activity and safety of rebastinib at 50 mg BID in combination with weekly paclitaxel for heavily pretreated pts with PROC, all of whom received prior carboplatin/paclitaxel, is encouraging. Simon stage 2 enrollment is ongoing. Clinical trial identification: NCT03601897.

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
Drug Name Trade Name Synonyms Drug Classes Drug Description
Gene Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown ovarian cancer not applicable Paclitaxel + Rebastinib Phase Ib/II Actionable In a Phase I/II trial, Rebastinib (DCC-2036) and Taxol (paclitaxel) combination therapy demonstrated acceptable safety, resulted in an objective response rate of 29% (5/17, 5 partial responses) and a clinical benefit rate of 82% in patients with advanced or metastatic platinum-resistant ovarian cancer, 62% (8/13) of patients had a CA-125 response (Annals of Oncology (2020) 31 (suppl_4): S629-S630; NCT03717415). detail...